Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2024-11-20
Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Conditions
- Non Hodgkin Lymphoma
Interventions
- OTHER
-
Long-term Follow-Up
No intervention
Sponsors & Collaborators
-
Miltenyi Biomedicine GmbH
lead INDUSTRY
Principal Investigators
-
Remi Kaleta, MD · Miltenyi Biomedicine GmbH
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-15
- Primary Completion
- 2039-12-01
- Completion
- 2039-12-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
NCT04052854 ·Status: NO_LONGER_AVAILABLE
-
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
NCT02569996 ·Status: COMPLETED ·Phase: PHASE3
-
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263 ·Status: RECRUITING ·Phase: PHASE2
-
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
NCT03145064 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
NCT06669143 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
NCT03761056 ·Status: COMPLETED ·Phase: PHASE2
-
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)
NCT00510133 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
NCT05635162 ·Status: RECRUITING ·Phase: PHASE2
-
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
NCT03870945 ·Status: COMPLETED ·Phase: PHASE1
-
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05797948 ·Status: UNKNOWN ·Phase: NA
-
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
NCT07316010 ·Status: SUSPENDED ·Phase: PHASE2
-
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
NCT04314843 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
NCT02660710 ·Status: COMPLETED ·Phase: PHASE2
-
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
NCT00582166 ·Status: TERMINATED ·Phase: PHASE2
-
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04458610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
NCT06504199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT03206970 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02763319 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
NCT01662102 ·Status: TERMINATED ·Phase: PHASE3
-
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
NCT05377307 ·Status: RECRUITING
-
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NCT05075603 ·Status: COMPLETED ·Phase: PHASE1
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156 ·Status: RECRUITING ·Phase: PHASE2